In summary, Tat-mediated lytic activation increases the risk and severity of Kaposi’s sarcoma, whereas LANA/STAT6–mediated latency promotes the survival of infected cells and viral persistence. This evidence concerns the gene STAT6 and Kaposi's sarcoma.